Thyroid hormone replacement for subclinical hypothyroidism.

BACKGROUND Subclinical hypothyroidism is defined as an elevated serum thyroid-stimulating hormone (TSH) level with normal free thyroid hormones values. The prevalence of subclinical hypothyroidism is 4% to 8% in the general population, and up to 15% to 18% in women who are over 60 years of age. There is considerable controversy regarding the morbidity, the clinical significance of subclinical hypothyroidism and if these patients should be treated. OBJECTIVES To assess the effects of thyroid hormone replacement for subclinical hypothyroidism. SEARCH STRATEGY We searched The Cochrane Library, MEDLINE, EMBASE and LILACS. Ongoing trials databases, reference lists and abstracts of congresses were scrutinized as well. SELECTION CRITERIA All studies had to be randomised controlled trials comparing thyroid hormone replacement with placebo or no treatment in adults with subclinical hypothyroidism. Minimum duration of follow-up was one month. DATA COLLECTION AND ANALYSIS Two authors independently assessed trial quality and extracted data. We contacted study authors for missing or additional information. MAIN RESULTS Twelve trials of six to 14 months duration involving 350 people were included. Eleven trials investigated levothyroxine replacement with placebo, one study compared levothyroxine replacement with no treatment. We did not identify any trial that assessed (cardiovascular) mortality or morbidity. Seven studies evaluated symptoms, mood and quality of life with no statistically significant improvement. One study showed a statistically significant improvement in cognitive function. Six studies assessed serum lipids, there was a trend for reduction in some parameters following levothyroxine replacement. Some echocardiographic parameters improved after levothyroxine replacement therapy, like myocardial relaxation, as indicated by a significant prolongation of the isovolumic relaxation time as well as diastolic dysfunction. Only four studies reported adverse events with no statistically significant differences between groups. AUTHORS' CONCLUSIONS In current RCTs, levothyroxine replacement therapy for subclinical hypothyroidism did not result in improved survival or decreased cardiovascular morbidity. Data on health-related quality of life and symptoms did not demonstrate significant differences between intervention groups. Some evidence indicates that levothyroxine replacement improves some parameters of lipid profiles and left ventricular function.

[1]  G. Guyatt,et al.  Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? , 1996, Journal of General Internal Medicine.

[2]  E. Mazzaferri.  Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults , 2007 .

[3]  J. Sundsfjord,et al.  Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  S. Gulseren,et al.  Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. , 2006, Archives of medical research.

[5]  G. Melnichenko,et al.  Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[6]  E. Vittinghoff,et al.  Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. , 2005, Archives of internal medicine.

[7]  Peter O'Leary,et al.  Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. , 2005, Archives of internal medicine.

[8]  A. Bergmann,et al.  Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. , 2005, Swiss medical weekly.

[9]  G. Kahaly,et al.  Thyroid hormone action in the heart. , 2005, Endocrine reviews.

[10]  E. Ferrannini,et al.  Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. , 2005, The Journal of clinical endocrinology and metabolism.

[11]  P. Box.  Thyroid status, disability and cognitive function, and survival in old age , 2005 .

[12]  A. D. de Craen,et al.  Thyroid status, disability and cognitive function, and survival in old age. , 2004, JAMA.

[13]  A. Hida,et al.  Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  S. Gorgulu,et al.  Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. , 2004, International journal of cardiology.

[15]  C. Palombo,et al.  Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  G. Marchesini,et al.  Health-related quality of life in patients with thyroid disorders , 2004, Quality of Life Research.

[17]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 2001, Minerva endocrinologica.

[18]  E. Pucci,et al.  Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment , 1993, The clinical investigator.

[19]  M. Christ-Crain,et al.  Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial , 2004, Osteoporosis International.

[20]  M. Christ-Crain,et al.  Prolactin dysregulation in women with subclinical hypothyroidism: effect of levothyroxine replacement therapy. , 2003, Thyroid : official journal of the American Thyroid Association.

[21]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[22]  M. Christ-Crain,et al.  Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. , 2003, Atherosclerosis.

[23]  B. Biondi,et al.  Effects of Subclinical Thyroid Dysfunction on the Heart , 2002, Annals of Internal Medicine.

[24]  E. Růžička,et al.  Changes of event related potential and cognitive processes in patients with subclinical hypothyroidism after thyroxine treatment. , 2002, Endocrine regulations.

[25]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[26]  E. Ferrannini,et al.  Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  C. Doré,et al.  A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. , 2002, The American journal of medicine.

[28]  V. Fatourechi.  Subclinical Hypothyroidism , 2002, Treatments in endocrinology.

[29]  J. Drewe,et al.  TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). , 2001, The Journal of clinical endocrinology and metabolism.

[30]  J. Franklyn,et al.  Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study , 2001, The Lancet.

[31]  D. Cooper.  Clinical practice. Subclinical hypothyroidism. , 2001, The New England journal of medicine.

[32]  E. Ferrannini,et al.  Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. , 2001, The Journal of clinical endocrinology and metabolism.

[33]  T. Jørgensen,et al.  Thyroid disorders in mild iodine deficiency. , 2000, Thyroid : official journal of the American Thyroid Association.

[34]  N. Powe,et al.  Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  C. Isles,et al.  Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. , 2000, QJM : monthly journal of the Association of Physicians.

[36]  G. Kahaly,et al.  Cardiovascular and atherogenic aspects of subclinical hypothyroidism. , 2000, Thyroid : official journal of the American Thyroid Association.

[37]  H. D. Cohen,et al.  American Thyroid Association guidelines for detection of thyroid dysfunction. , 2000, Archives of internal medicine.

[38]  M. Vanderpump,et al.  Population screening for autoimmune thyroid disease. , 2000, Endocrinology and metabolism clinics of North America.

[39]  P. Ladenson,et al.  When to treat mild hypothyroidism. , 2000, Endocrinology and metabolism clinics of North America.

[40]  D. O'reilly,et al.  Thyroid function tests—time for a reassessment , 2000, BMJ : British Medical Journal.

[41]  G. Canaris,et al.  The Colorado thyroid disease prevalence study. , 2000, Archives of internal medicine.

[42]  A. Hofman,et al.  Subclinical Hypothyroidism Is an Independent Risk Factor for Atherosclerosis and Myocardial Infarction in Elderly Women: The Rotterdam Study , 2000, Annals of Internal Medicine.

[43]  S. Waisbren,et al.  "Maternal Thyroid Deficiency During Pregnancy and Subsequent Neuropsychological Development of the Child" (1999), by James E. Haddow et al. , 2014 .

[44]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[45]  T. Jørgensen,et al.  The prevalence of thyroid dysfunction in a population with borderline iodine deficiency , 1999, Clinical endocrinology.

[46]  B. Biondi,et al.  Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[47]  R. Baumgartner,et al.  Subclinical Hypothyroidism in a Biethnic, Urban Community , 1999, Journal of the American Geriatrics Society.

[48]  A. Pinchera,et al.  The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. , 1999, The Journal of clinical endocrinology and metabolism.

[49]  L. Braverman.  Subclinical hypothyroidism and hyperthyroidism in elderly subjects: should they be treated? , 1999, Journal of endocrinological investigation.

[50]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[51]  M. Helfand,et al.  Screening for Thyroid Disease: An Update , 1998, Annals of Internal Medicine.

[52]  L. Murri,et al.  Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. , 1997, The Journal of clinical endocrinology and metabolism.

[53]  L. Kovács,et al.  Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long‐term iodine prophylaxis and abundant iodine intake , 1997, Clinical endocrinology.

[54]  J. Lekakis,et al.  Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. , 1997, Thyroid : official journal of the American Thyroid Association.

[55]  Á. Atallah,et al.  Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS). , 1997, Sao Paulo medical journal = Revista paulista de medicina.

[56]  B. O'Neill,et al.  The effect of thyroid hormone therapy on angiographic coronary artery disease progression. , 1997, The Canadian journal of cardiology.

[57]  A. Miserez,et al.  Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. , 1997, The Journal of clinical endocrinology and metabolism.

[58]  B. Uzzan,et al.  Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. , 1996, The Journal of clinical endocrinology and metabolism.

[59]  N. Powe,et al.  Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. , 1996, JAMA.

[60]  W. Busse,et al.  Ragweed immunotherapy in adult asthma. , 1996, The New England journal of medicine.

[61]  R. Westendorp,et al.  Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies , 1996, Clinical endocrinology.

[62]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[63]  Igor Sartori,et al.  Empirical Evidence of Bias. Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials , 1996 .

[64]  J. French,et al.  The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey , 1995, Clinical endocrinology.

[65]  George Davey Smith,et al.  Misleading meta-analysis , 1995, BMJ.

[66]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[67]  R. D'Agostino,et al.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. , 1994, The New England journal of medicine.

[68]  D. Ross.  Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. , 1993, The American journal of medicine.

[69]  E. Krenning,et al.  The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle‐aged women: associations with serum lipids , 1993, Clinical endocrinology.

[70]  G. Mason,et al.  Subclinical hypothyroidism: a modifiable risk factor for depression? , 1993, The American journal of psychiatry.

[71]  R. Joffe,et al.  Major depression and subclinical (grade 2) hypothyroidism , 1992, Psychoneuroendocrinology.

[72]  J. Staub,et al.  [Does isolated TSH elevation need treatment? Study of risk factors for the development of manifest hypothyroidism]. , 1992, Schweizerische medizinische Wochenschrift.

[73]  J. Franklyn,et al.  Prevalence and follow‐up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom , 1991, Clinical endocrinology.

[74]  J. Louvet,et al.  DECREASED HDL CHOLESTEROL IN SUBCLINICAL HYPOTHYROIDISM: THE EFFECT OF L‐THYROXINE THERAPY , 1990, Clinical endocrinology.

[75]  K. Caidahl,et al.  A DOUBLE‐BLIND CROSS‐OVER 12‐MONTH STUDY OF l‐THYROXINE TREATMENT OF WOMEN WITH ‘SUBCLINICAL’ HYPOTHYROIDISM , 1988, Clinical endocrinology.

[76]  H. Stähelin,et al.  LDL/HDL‐CHANGES IN SUBCLINICAL HYPOTHYROIDISM: POSSIBLE RISK FACTORS FOR CORONARY HEART DISEASE , 1988, Clinical endocrinology.

[77]  D. Cooper,et al.  L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. , 1984, Annals of internal medicine.

[78]  D. Rodbard,et al.  Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. , 1981, The Journal of clinical endocrinology and metabolism.

[79]  D. Appleton,et al.  THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY , 1977, Clinical endocrinology.

[80]  P. Fraser,et al.  Grades of hypothyroidism. , 1973, British medical journal.